

November 13, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 023

BSE Code: 532926

Dear Sir/ Madam,

National Stock Exchange of India Limited

Exchange Plaza, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051

Scrip Code: JYOTHYLAB

Sub: Newspaper publication – Un-audited Financial Results of the Company for the quarter and half- year ended September 30, 2025

With reference to the captioned subject, we are enclosing herewith copies of newspaper advertisement published in Business Standard (English) and Navshakti (Marathi) today, i.e. November 13, 2025, pertaining to Un-audited Financial Results of the Company for the quarter and half-year ended September 30, 2025.

Further, the aforesaid information is also available on the website of the Company at www.jyothylabs.com.

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you,

Yours faithfully, For Jyothy Labs Limited

Shreyas Trivedi Head – Legal & Company Secretary

Encl.: as above

Biocon expects debt rejig to give ₹300 cr booster to interest costs

As Biocon Biologics Ltd (BBL) charts its next phase of global expansion, Chief Executive Officer and Managing Director Shreehas Tambe outlines how the company is reshaping access, affordability, and growth in biosimilars. From California, in a video interview with Sohini Das and Aneeka Chatterjee, he talks of the ways in which BBL is working to stay ahead in competitive global markets. Edited excerpts:

Biocon Biologics is partnering California's CalRx initiative for affordable insulin. How significant is the tieup commercially, and does it indicate a broader shift toward government-linked procurement or

value-based models in key markets? ■ The announcement with the California government for CalRx-branded insulin glargine is path-breaking. It is an arrangement that complements our flexible commercial platform.

Through a partnership with Civica, a not-for-profit organisation, we enable direct distribution of insulin from the state to pharmacies, eliminating middlemen and making it affordable for Californians. California accounts for 20 per cent of America's insulin consumption, and this initiative opens a new, complementary channel for future state collaboration.

There are 50 states in the United States (US), and California is the first. We're already in discussion with several other states, as well as with partners like Civica and potentially TrumpRx, to explore similar initiatives. I would not call this a shift — it's not replacing our commercial channels. Rather, it's an example of the flexibility of our platform, which allows us to add another channel: Enabling direct-to-pharmacy access while continuing to serve exist-

Biocon has just settled structured debt obligations with Goldman Sachs and Kotak Mahindra Bank, and says this will cut interest costs from FY27. How much breathing room does this give Biocon Biologics

Total Income from operations (net)

Reserves (excluding Revaluation Reserves)

Earnings Per Share of face value Re 1/- each Basic earnings per share (Rs)

Diluted earnings per share (Rs)

Net Profit before tax

Net Profit after tax

Notes:

March 25, 2025

Place: Mumbai

Date: November 12, 2025

Particulars

Total comprehensive income for the period [comprising profit for the

period (after tax) and other comprehensive income (after tax)]

on the balance sheet?

■ We have been saying we will lighten the balance sheet and make it stronger. When we raised funds through a qualified institutional placement, we stated they would be used to retire structured debt. We have retired over ₹4,500 crore, closing out Goldman Sachs, Kotak Mahindra Bank, and soon Edelweiss. This will reduce interest costs by about ₹300 crore by FY27.

With debt easing and the business gaining traction, is the initial public offering (IPO) still on the table?

What's the realistic timeframe now? ■ We do not have any new developments to report at this point. As you may recall, Kiran Mazumdar-Shaw (Biocon chief) had mentioned that the Biocon board had formed a committee to evaluate the best way to monetise Biocon's investment in biologics — whether through an IPO or another route. Until the committee completes its review and reports back to the Biocon board, we would not have any updates.

The launch of Denosumab is on track. Which launches do you see as the next growth engine, and how are you positioning against bigger global biosimilar rivals in the US, Europe?

 At the close of FY25, we announced plans to launch five products in the US Of these, four have been launched in the first two quarters, a major milestone, given the negotiations on intellectual property, settlements, and litigation involved. Previously, we had four products in the US over seven



years, but by FY26, we'll have five launches within 12-18 months of March 2025. The fifth product, our athlete percept, is expected in the second half of next year. Though early, these launches position us strongly for sustained growth and competitive advantage.

The group has filed for semaglutide in Canada and Brazil. How significant are GLP-1 (glucagon-like peptide-1) products to Biocon's next phase of growth?

■ There is a sizable opportunity with semaglutide. Canada is expected to open up before other markets. Initially, there was an expectation that one of our Indian peers might enter sooner, but that seems to have been delayed somewhat. We already have the capability to develop and manufacture it.

Jyothy labs

Quarter Ended

30.06.2025

Unaudited

75,121

12,753

9,679

9,636

3,672

2.64

2.64

Not

Annualised

30.09.2024

Unaudited

73,307

13,559

10,493

10,470

3,672

2.86

2.86

Not

Annualised

JYOTHY LABS LIMITED

(CIN: L24240MH1992PLC128651)

Registered Office: Ujala House, Ramakrishna Mandir Road, Kondivita, Andheri East, Mumbai 400059

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

30.09.2025

Unaudited

73,606

11,869

8,776

8,734

3,672

2.39

2.39

The above unaudited financial results of the Company for the quarter and half year ended September 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. Further, Ms. M. R. Jyothy, Chairperson and Managing Director of the Company is duly authorized by the Board of Directors of the Company to sign the aforesaid financial results for the quarter and half year ended September

2 The Board of Directors, at its meeting held on March 25, 2025, had approved the sale of the Company's entire equity stake in Jyothy Kallol Bangladesh Limited ('JKBL' or 'the Subsidiary') to Kallol Enterprise Limited ('KEL' or 'the Buyer'), for an aggregate consideration of Rs. 210 Lacs. This sale of investment has resulted into a loss of Rs. 370 lacs shown under "Exceptional Items" in the statement of profit and loss. JKBL ceased to be a subsidiary of the Company from

Consequent to the sale of investment in the only subsidiary, with effect from March 25, 2025, the Company is now obliged to present only the standalone financial results for the quarter ended September 30, 2025. Accordingly, the comparative standalone segment information for the quarter and half year ended September 30, 2024 and the year ended March 31, 2025 was not subjected to limited review by the statutory auditors and has been compiled by the

For more details on results, visit investor center section of the Company's website at www.jyothylabs.com and financial result under corporates section of

Not

Annualised

But now, with our own commercial front in Canada through Biocon Biologics, we have a truly differentiated approach compared to many of our Indian peers. This sets us apart.

It also gives us an additional advantage because we are commercialising insulin in that region. So, alongside insulin, we can offer GLP-1 products through the same distribution channels, the same customers, and the same buying groups. This makes it a complementary offer that allows us to leverage existing relations.

You recently inaugurated a facility for oral solids in the US. Any plans to expand the manufacturing footprint?

■ We recently inaugurated our commercial manufacturing facility in Cranbury, New Jersey. Establishing it in the US was a strategic move. Being closer to the market, it provides logistical and procurement advantages. It's a sound business decision that strengthens our competitive position and supports long-term sustainability.

Given your partnership with Civica for insulin manufacturing in the US, are you exploring a similar local production model for semaglutide?

■ We have established a partnership with Civica to produce insulin domestically. Under this collaboration, we supply the drug substance, and Civica manufactures insulin in the US, for the US. This decision was made well before recent trade discussions. It was based purely on business rationale. Producing close to our patients and markets simply makes sense.

The same principle will guide our approach to semaglutide manufactur ing. If it makes business sense to produce locally, based on demand and market dynamics, we will. Wherever there is a large consumption base, we aim to be close to our customers.

(Rs. in lacs)

Year Ended

31.03.2025

Audited

2,84,392

48,955

37,117

36,947

3,672

10.11

10.11

Annualised

1,34,589

Half Year Ended

30.09.2024

Unaudited

1,47,425

26,809

20,676

20,630

3,672

5.63

5.63

Not

Annualised

30.09.2025

Unaudited

1,48,727

24,622

18,455

18,370

3,672

5.03

5.03

Not

Annualised



SHINE JACOB

Chennai, 12 November

Andhra Pradesh has signed an agreement with New York-headquartered Tillman Global Holdings to develop a 300 megawatt (Mw) hyperscale data centre campus called TDGAP1 in Visakhapatnam for a proposed investment of ₹15,000 crore.

The project will be facilitated through the Andhra Pradesh Economic Development Board

(APEDB) and strengthen Visakhapatnam's reputation as a digital THE PROJECT WILL infrastructure hub in the SPAN ABOUT 40 Indo Pacific, said a statement. ACRES, AND IS

A memorandum of under- EXPECTED TO standing (MoU) between the two GENERATE 200-300 sides sets a facilitation framework DIRECT JOBS AND for time-bound development 800–1,000 INDIRECT within 12 months, with APEDB JOBS BY 2028 coordinating investor support and inter-agency facilitation under

applicable state and central government pol- Holdings will strengthen our digital backbone, icies. The project will span about 40 acres and is expected to generate 200-300 direct jobs and 800-1,000 indirect jobs by 2028 through growth in allied services, logistics, Cloud networks, and ancillary units.

Tillman, a digital infrastructure company, will bring investment, technology, planning and design, and critical equipment for TDGAP1. All land allotments, incentives, and benefits will be undertaken by relevant state departments through due process, including participation in

applicable tender processes.

"Andhra Pradesh offers a compelling combination of coastal connectivity, progressive governance, and a rapidly expanding digital economy," said Sachit Ahuja, co president, Tillman Global Holdings. "With TDGAP1, we aim to build a world class 300 MW campus in Visakhapatnam that anchors long term digital infrastructure, creates high quality jobs, and catalyses a broader ecosystem of services and

innovation. We value the state's facilitation through APEDB and look forward to executing this project in atime bound manner".

"This MoU underscores Andhra Pradesh's strategy to position Visakhapatnam as a premier data center hub," said Nara Lokesh, the state's Minister for IT, Electronics and HRD. "The proposed Rs. 15,000 crore investment by Tillman Global

generate direct and indirect employment for our youth, and attract allied investments across energy, networks, cloud, and services. The government will facilitate within policy to ensure swift, transparent progress.

development follows Google's The announcement of a \$15 billion investment to establish an artificial intelligence data centre in Andhra Pradesh — its largest in India — in partnership with Adani Group and Airtel, including

Syrma plans to make printed circuit boards at Andhra plant: MD

AASHISH ARYAN

New Delhi, 12 November

Electronic manufacturing services (EMS) firm Syrma SGS plans to start the trial production of printed circuit boards (PCB) from its upcoming Andhra Pradesh manufacturing unit by December 2026 to facilitate the commercial production from the unit by March 2027, the company's Managing Director JS Guiral said.

"Once I start my trial production, I approach my customers for the approvals and other formalities," Gujral told Business Standard.

The land for the plant had been provisionally allotted to the company and the process for registering it is underway, he said. The PCB manufacturingplant, for which Syrma SGS has received the central government's approval under the Electronics Component Manufacturing Scheme (ECMS), is located near Naidupeta in Tirupati district of Andhra Pradesh. The unit, spread over 7 lakh square feet, should be ready in the next 12-13 months. Guiral said.

"We expect to break ground for construction sometime in about 20 by next year from the the next month. We have also 10 we have currently," he said.



Syrma SGS is confident of crossing the 9% Ebitda target for FY26: MD JS Gujral

given the plans for approval. I am confident that we should be able to start construction very soon," Gujral said.

The total investment in the plant is likely to be ₹1,595 crore and is expected to create 2,170 high-skill jobs. Overall, Syrma SGS is confident of crossing the 9 per cent earning before interest, taxes, depreciation, and amortisation (Ebitda) target for this financial year, Guiral said.

"What excites us are the new customers that we have onboarded, which are bigticket size customers. They should be giving us the revenue from next year. We also expect our bracket of ₹100crore customers going up to

AI hub to cater to user demand

Google's \$15 bn

AASHISH ARYAN New Delhi, 12 November

Google expects an increase in demand from customers with the setting up of its \$15 billion artificial intelligence (AI) data hub in Visakhapatnam, said Matt Renner, president of global revenue at Google Cloud.

'There is a very progressive set of demands from firms in India, especially in the business-to-business and business-to-consumer spaces, when it comes to AI. We are seeing very broad and diverse demand from customers in India and trying to meet that with our infrastructure,' Renner said during a press conference on Wednesday.

Sovereign in-country investments, such as the one made by Google in Visakhapatnam, help the company assure its customers that their data will remain safe and within the geographical boundaries of their country, Renner said.

Google, he said, had "very advanced sovereign solutions" to meet any regulatory demands that Google Cloud's customers could have. In October this year, Google announced a \$15 billion investment over the next

Svatantra Microfin Private Limited Regd. Office: Sunshine Tower, Level 20, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400013 Web.: www.svatantramicrofin.com Email: secretarial@svatantra.aditvabirla.com Tel: + 912261415900 CIN: U74120MH2012PTC227069



Extract of Statement of unaudited financial results for the quarter and half year ended 30 September, 2025 [Regulation 52 (8), read with Regulation 52 (4), of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015")]

(Rs. In Lakhs except per share data & ratios

		Standaione						
Sr.		Quarte		Half year ended	Year ended			
No.	Particulars	30 September 2025	30 September 2024	30 September 2025	31 March 202			
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			
1	Total Income from Operations	43,607	43,759	82,907	160,415			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	6,523	7,191	9,724	21,590			
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	6,523	7,191	9,724	21,590			
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	4,847	5,360	7,206	16,490			
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	4,910	5,454	7,234	16,358			
6	Paid up Equity Share Capital	62,689	25,205	62,689	62,689			
7	Reserves (excluding Revaluation Reserve)	279,516	54,358	279,516	272,276			
8	Securities Premium Account	272,276	4	221,020	221,020			
9	Net worth (including Compulsory Convertible Non-Cumulative Preference Shares)	342,205	255,063	342,205	334,965			
10	Paid up Debt Capital / Outstanding Debt	564,482	567,755	564,482	476,800			
11	Outstanding Redeemable Preference Shares	-	-	-	-			
12	Debt Equity Ratio	1.65	2.23	1.65	1.42			
13	Earnings Per Share (of Rs. 10/- each)							
	1. Basic:	0.77	1.05	1.15	2.97			
	2. Diluted:	0.77	1.04	1.15	2.96			
14	Capital Redemption Reserve	NA	NA	NA	NA			
15	Debenture Redemption Reserve	NA	NA	NA	NA			
16	Debt Service Coverage Ratio	NA	NA	NA	NA			
17	Interest Service Coverage Ratio	NA	NA	NA	NA			

Note: a) The above standalone financial results for the quarter and half year ended 30th September 2025 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meetings held or 07 November 2025 and 12 November 2025 respectively.

b) The above is an extract of the detailed format of quarterly Financial Results filed with the BSE Limited under Regulation 52 of the SEBI Listing Regulations, 2015. The full format of the quarterly financial results is available on the website of the BSE Limited (www.bseindia.com) and on the Company's website (https://investors.svatantramicrofin.com/regulation-52-financial-results-and

c) For the other line items referred in Regulation 52(4) of the SEBI Listing Regulations, 2015, pertinent disclosures have been made to the BSE Limited and can be accessed on the website of the BSE Limited (www.bseindia.com) and on the Company's website (https://investors.syatantramicrofin.com/regulation-52-financial-results-and-disclosure) By order of the Board of Directors For Svatantra Microfin Private Limited

Ananyashree Birla (Director)

Date: 12 November 2025

Place : Mumbai



management, as the Company had then published consolidated segment results which were subject to such review.

For and on behalf of the Board of Directors Chairperson and Managing Director DIN: 00571828

SPECIAL WINDOW FOR RE-LODGEMENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

As mandated by SEBI a 'Special Window' has been allowed from July 07, 2025 to January 06, 2026 to facilitate re-lodgement of physical share transfer request that were originally lodged before April 1, 2019 but were rejected / returned due to deficiencies. Investors who missed the earlier cut-off of March 31, 2021, are encouraged to utilise this special window and submit the requisitie documents to the Company / Company's RTA- MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited).



(Rs. in Lakh except EPS										
Particulars	0	uarter ende	d	Half Year	Year Ended					
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025				
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited				
Total Income from Operations	1.80	30.00	0.00	31.80	0.00	0.00				
Net Profit / (Loss) for the period before Tax	(7.54)	22.58	(0.85)	15.04	(2.35)	(107.93)				
Net Profit / (Loss) for the period after tax	(7.54)	22.58	(0.85)	15.04	(2.35)	(107.93)				
Total Comprehensive Income for the period	(7.54)	22.58	(0.85)	15.04	(2.35)	(107.93)				
Equity Share Capital	130.00	130.00	130.00	130.00	130.00	130.00				
Reserves	-	-	-			(225.89)				
Earnings Per Share in Rs.										
(Face Value Rs. 100/- each)										
Basic	(5.80)	17.37	(0.65)	11.57	(1.81)	(83.02)				
Diluted	(5.80)	17.37	(0.65)	11.57	(1.81)	(83.02)				

Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the said Financial Results is available on the Stoc xchange website www.bseindia.com and on company's website www.

Place: Mumbai Date: 12th November, 2025



For Bombay Potteries & Tiles Limited Manoj Vasudev Wadhw Chairman and Managing Director

D & H India Limited

CIN: L28900MH1985PLC035822

Regd. Office: A - 204, Kailash Esplanade, Opp. Shreyas Cinema, L.B.S Marg, Ghatkopar (West), Mumbai - 400 086 Phone: 022-49711885, Email: ho@dnhindia.com Website:www.dnhindia.com

Extract of Un Audited Consolidated Financial Results for the Quarter and Half Year ended 30.09.2025 (Rs. In Lacs)

Sr. No.	Particular	Quarter ended 30.09.2025 Un-Audited	Quarter ended 30.06.2025 Audited	Quarter ended 30.09.2024 Un-Audited	Year ended 31.03.2025 Audited
1.	Total Income from operation (Net of GST duty)	6561.71	5290.21	5031.30	20912.64
2.	Net Profit /(Loss) for the period before tax and Exceptional items	193.32	175.27	144.03	755.71
3.	Net Profit /(Loss) for the period before tax after Exceptional items	193.32	175.27	144.03	755.71
4.	Net Profit /(Loss) for the period after tax	157.68	134.07	65.07	515.29
5.	Total Comprehensive Income for the period (Comprising Profit/(loss)				
	for the period (after tax) & Other comprehensive income (after tax)	150.41	143.13	84.67	524.24
6.	Paid-Up Equity Share Capital (Face Value Rs. 10/- each)	818.80	818.80	818.80	818.80
7.	Reserve excluding Revaluation Reserve as per Balance Sheet of previous year				3879.56
8.	Earning per share				
	Basic	1.84	1.76	1.03	6.40
	Diluted	1.84	1.76	1.03	6.40

Key Standalone Information

Sr. No.	Particular	ended 30.09.2025 Un-Audited	ended 30.06.2025 Audited	ended 30.09.2024 Un-Audited	ended 31.03.2025 Audited
1. 2. 3.	Turnover (Net Sales) Profit Before Tax Profit After Tax	6561.71 193.34 157.69	5290.21 175.29 134.08	5031.29 144.09 65.13	20912.64 756.53 516.08
-				<u> </u>	

Note:1. The above is an extract of the detailed format of Quarterly / Annual Financial Result filed with the Stock

Note:1. The above is an extract of the detailed format of Quarterly / Annual Financial Result filed with the Stock

On the SERI (Lieting and other Discolsure Requirements) Regulation, 2015. The full format of the Quarterly /Year Financial Results are avaliable on the Stock Exchange website viz. www.bseindia.com. The same is also available on the Company website viz.www.dnhindia.com

2. The above results were reviewed by the Audit Committee and therefore approved and taken on record by the Board o Directora at their meeting held on 12th November 2025

Place: Indore Date: 12.11.2025

For D & H India Limited Harsh Vora - Managing Director

cítì

CITICORP FINANCE (INDIA) LIMITED

Regd Office: B7, 5th Floor, Nirlon Knowledge Park, Goregaon (East), Mumbai - 400063.
CIN: U65910MH1997PLC253897, Tel No: 022 26532160, Fax: 022 26532215, website: Citicorp Finance (India) Limited | Citi India EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025

Sr.		Quarte	Quarter Ended			
No.	Particulars	September 30, 2025	September 30, 2024	March 31, 2025		
		Unaudited	Unaudited	Audited		
1	Total Income from Operations	13,904	20,569	58,863		
2	Net Profit(+)/Loss(-) for the period (before Tax, Exceptional and/or Extraordinary items)	5,550	13,935	33,02		
3	Net Profit(+)/Loss(-) for the period before tax (after Exceptional and/or Extraordinary items)	5,550	13,935	33,02		
4	Net Profit(+)/Loss(-) for the period after tax (after Exceptional and/or Extraordinary items)	3,325	10,717	24,13		
5	Total Comprehensive Income for the period [Comprising of Profit (+)/Loss (-) for the period (after tax) and Other Comprehensive Income (after tax)]	3,299	10,854	24,19		
6	Paid-up equity share capital (Face Value: Rs 7.50 each, fully paid)	289,330	289,330	289,33		
7	Reserves excluding Revaluation Reserves	101,895	129,181	109,09		
8	Securities Premium Account	-	-			
9	Net worth (Refer Note 6)	391,225	418,511	398,42		
10	Paid-up Debt Capital / Outstanding Debt	371,660	202,075	436,06		
11	Outstanding Redeemable Preference Shares	NIL	NIL	N		
12	Debt Equity Ratio (Refer Note No. 5)	0.95	0.48	1.0		
13	Earnings Per Share (EPS)					
	(i) Basic EPS (Rs.)	0.09	0.28	0.6		
	(ii) Diluted EPS (Rs.)	0.09	0.28	0.6		
14	Security Cover	1.49	1.48	2.8		
15	Capital Redemption Reserve	NA	NA	N		
16	Debenture Redemption Reserve	NA	NA	N		
17	Debt Service Coverage Ratio	NA	NA	N		
18	Interest Service Coverage Ratio	NA	NA	N		

- The above is an extract of the detailed format of the financial results filed with the National Stock Exchange of India under Regulation 52 of
 the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed format of
 the quarterly financial results is available on the websites of the Stock Exchange and on the website of the Company (Citicorp Finance
 (India) Limited | Citi India).
- The Statement referred in Regulation 52(4) of the SEBI (Listing Obligations and Discion the website of the company (Citicorp Finance (India) Limited | Citi India).
- 3. The Company is a Non-Banking Finance Company registered with the Reserve Bank of India.
- 4. The above financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held or
- 6. Net worth= Paid-up share capital + Reserves Deferred Revenue Expenditure
- $7. \quad \text{Previous period figures have been regrouped/reclassified, wherever necessary, to conform to current financial period/quarter and the property of the$

Citicorp Finance (India) Limited

M

Date: November 12, 2025 Managing Director

Place: Mumbai

PRECISION WIRES INDIA LIMITED

CIN: L31300MH1989PLC054356



EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

	(₹ in Lakhs except Per Share Data)									
Sr.		Quarter	Ended	Half Yea	r Ended	Year Ended				
No.	Particulars	30.09.2025	30.06.2025	30.09.2025	30.09.2024	31.03.2025				
		(Un-audited)	(Un-audited)	(Un-audited)	(Un-audited)	(Audited)				
1	Total Income from Operations	1,23,740.50	1,11,557.34	2,35,297.86	1,99,897.85	4,03,562.07				
2	Net Profit /(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	4,842.90	3,617.66	8,460.56	5,571.37	12,037.03				
3	Net Profit/(Loss) for the period (before Tax, after Exceptional and/or Extraordinary items)	4,842.90	3,617.66	8,460.56	5,571.37	12,037.03				
4	Net Profit/(Loss) for the period (after Tax, after Exceptional and/or Extraordinary items)	3,561.19	2,708.63	6,269.82	4,150.28	9,004.01				
5	Total Comprehensive income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income(after tax)]	3,561.19	2,708.63	6,269.82	4,150.28	8,945.06				
6	Equity Share Capital	1,800.41	1,786.58	1,800.41	1,786.58	1,786.58				
7	Reserves excluding Revaluation Reserves as per Balance Sheet					55,837.28				
8	Earning per Share (before Extraordinary Items) of ₹1/- each (quarterly not annualised)	1.98	1.52	3.48	2.32	5.04				
9	Earning per Share (after Extraordinary Items) of ₹1/- each (quarterly not annualised)	1.98	1.52	3.48	2.32	5.04				

Notes

- 1 The above Results were reviewed and recommended by the Audit Committee and were taken on record and approved by the Board of Directors in their respective meeting held on 12th November, 2025.
- The Board has declared an Interim Dividend for FY 2025-26 @ ₹ 0.35 (35 %) per equity share of ₹ 1 each fully paid-up The Record date fixed for the purpose of determining the entitlement of members for the Interim Dividend is Tuesday, 18th November, 2025 and said Interim dividend will be paid on or before 11th December, 2025 to those members entitled thereto.
- The above is an extract of the detailed format of Quarterly/half year ended results filed with the Stock exchange under Regulation 33 of the SEBI (Listing and other disclosure Requirements) Regulations, 2015. The full format of results are available on the website of the Company i.e. http://precisionwires.in and on the website of stock exchanges i.e. www.bseindia.com and www.nseindia.com

Place : Mumbai Date: 12th November, 2025



By order of the Board Milan M. Mehta Chairman & Managing Director

मुंबई, गुरुवार, दि. १३ नोव्हेंबर २०२५

स्थावर मालमत्तेच्या विक्रीसाठी विक्री सूचना सिक्यरिटी इटरेस्ट (एन्फोर्समेंट) नियम 2002 चा नियम 8(6) आणि नियम 9(1)च्या नियमाना सिक्युरिटायझेशन ॲण्ड रिकन्सट्क्शन ऑफ फायनान्शियल ॲसेट्स ॲण्ड एन्फोर्समेंट ऑफ सिक्युरिटी इंटरेस्ट ॲक्ट, 2002 अन्वये स्थावर मालमत्तेच्या विक्रीसाठी ई-लिलावाची विक्री सूचना

परिशिष्ट IV-A

सर्वसामान्य जनतेला आणि विशेषतः कर्जदारांना तसेच हमीदारांना सूचीत करण्यात येते की, खाली वर्णन केलेली स्थावर मालमत्ता सुरक्षित कर्जदात्यांनी गहाण केली गेली होती त्या मालमत्तेवर सुरक्षित कर्जदात्याच्या प्राधिकृत अधिकारीने **सम्मान कॅपिटल लिमिटेड (पूर्वी इंडियाबुल्स हार्ऊसिंग** फायनान्स लि. म्हणून ओळखले जायचे) [CIN : L65922DL2005PLC136029] (''स्रक्षित कर्जदार'') तर्फे वास्तविक ताबा घेतला आहे. ज्याचा 29.11.2025 रोजी संध्याकाळी 05.00 ते 06.00 पर्यंत ''जेथे आहे'', ''जसे आहे'' आणि ''जे काहीपण आहे'', ची वसूली साठी कर्ज खाते न HHLTHN00243242 साठी रु. 24,34,543/- (रुपये चोवीस लाख चौतीस हजार पाचशे त्रेचाळीस फक्त) उर्वरित मूलधन, उर्वरित (विलंबशुल्क) आणि दिनांक 07.11.2025 पर्यंत व्याज कर्जांच्या अटींनुसार कर्ज करार आणि इतर संबंधित कर्ज दस्तऐवजांच्या संदर्भात लागू भविष्यातील व्याज 08.11.2025 पासून कायदेशीर खर्च किंवा इतर शुल्का सह प्रभावी होऊन जो शशिकात जगन्नाथ कोळी, **मनिषा जगन्नाथ कोळी आणि सुरेश रुहबहादूर छेन्री** यांची मालमत्ता सुरक्षित कर्जदाराच्या द्वारे कर्जाच्या वसूली साठी विकली जाईल.

सदर मालमत्तेच्या लिलावासाठी आरक्षित रक्कम रु. 17,46,000/- (रुपये सतरा लाख सेहेचाळीस हजार फक्त) आणि अर्नेस्ट मनी डिपॉजिट (''ईएमडी'') रु. 1,74,600/- (रुपये एक लाख **चौ-याहत्तर हजार सहाशे फक्त)** म्हणजेच अनामत ठेव रक्कम राखीव किंमतीच्या 10% असेल. स्थावर मालमत्तेचे वर्णन

फ्लॅट क्र. 504, आश्रय पर्ल, ए - विंग, शिव मंदिराजवळ, मौजे पाले, अंबरनाथ पर्व, ठाणे महाराष्ट्र - 421501.

विकीच्या तपशीलवार नियम व अटींसाठी कपया सरक्षित कर्जदाराच्या www.sammaancapital.com या वेबसाईटवरील लिंक पाहा; सपर्क क्र. : 0124-6910910, +91 7065451024, ई–मेल auctionhelpline@sammaancapital.com. बोली लावण्यासाठी, www.auctionfocus.in वर लॉग ऑन करा. सही /

तारीख: 10.11.2025 स्थळ : ठाणे

सम्मान कॅपिटल लिमिटेड (पूर्वी इंडियाबुल्स हाऊसिंग फायनान्स लि. म्हणून ओळखले जायचे)

ASHIANA AGRO INDUSTRIES LIMITED

Reg. Office: No.34, Andal Nagar, Baluchetty Chatram, Kancheepuram Taluk, Kancheepuram Distt.- 631551 (Tamil Nadu) Tel No.: +91-44-28344820, Website: www.aail.ir Extract of Standalone Unaudited Financial Results for the Quarter and Six Months Ended 30th September, 2025

		Quarter Ended			Six Mont	Year Ended	
SI.	Particulars	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
NO		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations Including Other Income (Net)	29.71	22.27	26.66	51.98	46.03	96.36
2	Net Profit/(Loss) for the period (Before Tax, Exceptional Items and / or Extraordinary items)	2.17	(0.53)	5.71	1.64	6.64	11.36
3	Net Profit / (Loss) for the period before Tax (after Exceptional Items and / or Extraordinary items)	2.17	(0.53)	5.71	1.64	6.64	11.36
4	Net Profit / (Loss) for the period after Tax (after Exceptional Items and / or Extraordinary items)	1.77	(0.53)	1.15	1.24	2.08	8.50
5	Total Comprehensive Income for the period (Comprising Profit/ (Loss) for the period (after tax) and other comprehensive Income (after tax)	1.77	(0.53)	1.15	1.24	2.08	8.50
6	Paid up Equity Share Capital (Face Yalue of Rs.10/- per share)	460.00	460.00	460.00	460.00	460.00	460.00
7	Reserves (exduding Revaluation Reserve) as shown in the Audited Balance sheet of previous year	-	-	-	-	-	201.27)
8	Earning Per Share (EPS) (in Rs.) (Face Value of Rs.10/- each)						
	(a) Basic and diluted EPS before Extraordinary items	0.04	(0.01)	0.03	0.03	0.05	0.18
П	(b) Basic and diluted EPS after Extraordinary items	0.04	(0.01)	0.03	0.03	0.05	0.18

Note: 1) The above results have been reviewed by the Audit Committee subject to limited review by the statutory auditors of the company and approved by the Board of Director in their meeting held on November 12, 2025.

 This statement has been prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Com Accounts) Rules, 2014. 3) The above is an extract of the detailed format of the Standalone Unaudited Financial Results for the Quarter and Six months ended September 30, 2025 filed with the Stoc

exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Sb months ended September 30, 2025 are available on website of the Stock Exchange at www.bseindia.com and also on the Company's website at www.aail.in. For Ashiana Agro Industries Limite

Whole Time Directo Date : 12.11.2025 DIN: 02438906

R LALAB Indef

INDEF MANUFACTURING LIMITED

Corporate Office: 501-504, Shelton Cubix, Sector 15, Plot 87, CBD Belapur, Navi Mumbai 400 614. Registered Office: Bajaj Bhavan, 2nd Floor, 226, Nariman Point, Mumbai-400021

Ph: +91 022-45417309 / 06 Email: cs1@indef.com URL: www.indef.com CIN: L29308MH2022PLC390286



Extract of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Half Year Ended September 30, 2025

(Rs. In Lakhs)

			ALONE	CONSOLIDATED					
SN	L	Quarter ended		Half Year Ended Year ended		Quarter ended		Half Year Ended	Year ended
NO	PARTICULARS	30-Sept-25	30-Sept-24	30-Sept-25	31-Mar-25	30-Sept-25	30-Sep-24	30-Sept-25	31-Mar-25
NO			Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	5064.89	4860.96	9410.02	19369.43	5200.68	4860.96	9700.8	19559.55
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)#	805.24	1120.03	1587.36	4204.68	742.23	1116.49	1499.18	4195.05
	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)#	805.24	1120.03	1587.36	4204.68	742.23	1116.49	1499.18	4195.05
4 1	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	670.07	1131.07	1256.52	3423.92	625.95	1128.42	1191.16	3416.03
	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	668.20	1127.42	1252.78	3427.38	624.08	1124.77	1187.42	3419.50
6	Equity Share Capital	320.00	320.00	320	320	320	320	320	320
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet	-			24978.21				24970.33
8	Earnings Per Share (of Rs. 1.00 each) (for continuing and discontinued operations) - Basic & Diluted##	2.09	3.53	3.93	10.70	1.96	3.53	3.72	10.68

Place: Mumbai

Date: November 12, 2025

The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. The above is an extract of the detailed format of Quarter and Half year ended Un-Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarter and Half year ended Un-Audited Financial Results are available on the websites of www.bseindia.com; www.nseindia.com and also on Company's website at www.indef.com and can be accessed by scanning below

- 2. Previous quarter / year figures have been appropriately recasted, regrouped and reclassified wherever necessary to confirm to the current year presentations
- #Company does not have any exceptional and extraordinary items to report for the above period.
 ##EPS is not annualised for the quarter ended September 30,2025 and half year ended September 30, 2025.



On behalf of Board of Directors of Indef Manufacturing Limited Shekhar Bajaj Chairma

DIN-00089358

Jyothy labs

ज्योती लॅब्स लिमिटेड

सीआयएन : एल२४२४०एमएच१९९२पीएलसी१२८६५१

नोंदणी कार्यालय : उजाला हाऊस, राम कृष्ण मंदिर रोड, कोंडीविटा, अंधेरी (प्), मुंबई - ४०० ०५९.

३० सप्टेंबर, २०२५ रोजी समाप्त तिमाही आणि अर्धवर्षाकरिता वित्तीय निष्कर्षांचा अहवाल

रक्कम (रू. लाखात)

		तिमाही समाप्ती			अर्घवर्ष	वर्ष समाप्ती	
तपशील		३०.०९.२०२५	३०.०६.२०२५	३०.०९.२०२४	३०.०९.२०२५	३०.०९.२०२४	३१.०३.२०२५
		अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	अलेखापरीक्षित	लेखापरीक्षित
प्रवर्तनामधून एकूण उत्पन्न (निव्व	<u></u>	७३,६०६	७५,१२१	७०६,६७	१,४८,७२७	१,४७,४२५	२,४४,३९२
कर पूर्व निव्वळ नफा		११,८६९	१२,७५३	१३,५५९	२४,६२२	२६,८०९	४८,९५५
कर पश्चात निव्वळ नफा		३७७,ऽ	९,६७९	१०,४९३	१८,४५५	२०,६७६	३७,११७
सदर कालावधीसाठी सर्वसमावेश	राक एकूण उत्पन्न (सदर कालावधीसाठी नफा						
समाविष्ट (कर पश्चात) आणि अन्	न्य सर्वसमावेशक उत्पन्न (कर पश्चात))	४६७,ऽ	९,६३६	१०,४७०	१८,३७०	२०,६३०	३६,९४७
भरणा झालेले समभाग भांडवल		३,६७२	३,६७२	३,६७२	३,६७२	३,६७२	३,६७२
राखीव (पुन:मुल्यांकित राखीव व	वगळून)						१,३४,५८९
दर्शनिमूल्य प्रत्येकी रू. १ च्या प्र	ती भाग उत्पन्न						
प्रती भाग मुलभूत उत्पन्न (रू.)		7.39	२.६४	२.८६	4.03	५.६३	१०.११
प्रती भाग सौमिकृत उत्पन्न (रू)		7.39	२.६४	२.८६	4.03	५.६३	१०.११
		वार्षिक नाही	वार्षिक नाही	वार्षिक नाही	वार्षिक नाही	वार्षिक नाही	वार्षिक

- १. कंपनीच्या ३० सप्टेबर, २०२५ रोजी समाप्त तिमाही आणि अर्धवर्षाच्या उपरोक्त अलेखापरीक्षित वित्तीय निष्कर्षांचे लेखापरीक्षण समितीद्वारे पुनरावलोकन करण्यात आले आणि कंपनीच्या संचालक मंडळाने त्यांच्या १२नोव्हेंबर, २०२५ रोजी झालेल्या सभेमध्ये मंजूर केले. पुढे, मिस. एम. आर. ज्योती, कंपनीचे अध्यक्ष आणि व्यवस्थापकीय संचालक, ३० सप्टेंबर, २०२५ रोजी समाप्त तिमाही आणि अर्धवर्षाच्या उपरोक्त वित्तीय निष्कर्षांवर स्वाक्षरी करण्यासाठी कंपनीच्या संचालक मंडळाद्वारे योग्य पद्धतीने अधिकृत आहेत.
- २. २५ मार्च २०२५ रोजी झालेल्या संचालक मंडळाच्या बैठकीत, ज्योती कल्लोल बांगलादेश लिमिटेड) ('जेकेबीएल' किंवा 'उपकंपनी') मधील कंपनीचा संपूर्ण इक्विटी हिस्सा कल्लोल एंटरप्राइझ लिमिटेड ('केईएल' किंवा 'खरेदीदार') ला एकूण २१० लाख रूपयांच्या मोबदल्यात विकण्यास मान्यता दिली होती. गुंतवणुकीच्या या विक्रीमुळे नफा आणि तोटचाच्या विवरणपत्रात ''अपवादात्मक बाबी'' अंतर्गत दर्शविलेले ३७० लाख रूपये इतके नुकसान झाले आहे. जेकेबीएल दिनांक २५ मार्च २०२५ पासून कंपनीची उपकंपनी म्हणून बंद झाली.
- ३. २५ मार्च २०२५ पासून एकमेव उपकंपनीतील गुंतवणुकीच्या विक्रीमुळे, कंपनीला आता ३० सप्टेंबर २०२५ रोजी संपलेल्या तिमाहीतील फक्त स्वतंत्र वित्तीय निष्कर्ष सादर करावे लागतील. त्यानुसार, ३० सप्टेंबर २०२४ रोजी संपलेल्या तिमाही आणि ३१ मार्च २०२५ रोजी संपलेल्या वर्षासाठी तुलनात्मक स्वतंत्र विभाग माहिती वैधानिक लेखापरीक्षकांकडून मर्यादित पुनरावलोकनाच्या अधीन नव्हती आणि व्यवस्थापनाने ती संकलित केली आहे, कारण कंपनीने त्यावेळी एकत्रित विभाग निष्कर्ष प्रकाशित केले होते जे अशा पुनरावलोकनाच्या अधीन होते.
- ४. निष्कर्षांच्या अधिक तपशिलासाठी, कंपनीच्या संकेतस्थळ www.jyothylabs.com येथे इन्व्हेस्टर सेंटर विभागाला आणि स्टॉक एक्स्चेंजचे संकेतस्थळ अर्थात www.nseindia.com आणि www.bseindia.com च्या कॉर्पोरेट सेक्शन अंतर्गत फायनान्शीयल रिझल्ट सेक्शनला भेट द्या.

स्थळ : मुंबई दिनांक : १२ नोव्हेंबर, २०२५



संचालक मंडळाकरिता आणि वतीने एम. आर. ज्योती अध्यक्ष आणि व्यवस्थापकीय संचालक डिआयएन: ००५७१८२८

भौतिक शेअर्सच्या हस्तांतरण विनंत्या पुन्हा दाखल करण्यासाठी विशेष विंडो

'सेबीने आदेश दिल्यानुसार, १ एप्रिल २०१९ पूर्वी दाखल केलेल्या परंतु त्रुटींमुळे नाकारल्या गेलेल्या / परत केलेल्या''भौतिक शेअर हस्तांतरण विनंती पुन्हा दाखल करण्यासाठी ०७ जुलै २०२५ ते ०६ जानेवारी २०२६ पर्यंत 'विशेष विंडो'''ला परवानगी देण्यात आली आहे. ३१ मार्च २०२१ चा पूर्वीचा कट-ऑफ चुकवलेल्या गुंतवणूकदारांना या विशेष विंडोंचा'' वापर करण्यास आणि कंपनी / कंपनीच्या आरटीए- एमयूएफजी इनटाइम इंडिया प्रायव्हेट लिमिटेड (पूर्वीची लिंक"इनटाइन इंडिया प्रायव्हेट लिमिटेड म्हणून ओळखली जाते) कडे आवश्यक कागदपत्रे सादर करण्यास प्रोत्साहित केले"जात आहे.



